Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression

Journal of Ovarian Research

Volumn 4, Issue 1, 2011, Pages

  Agnani, Deep ^a   Camacho Vanegas, Olga ^a   Camacho, Catalina ^a   Lele, Shashi ^b   Odunsi, Kunle ^b   Cohen, Samantha ^c   Dottino, Peter ^c   Martignetti, John A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Glutathione peroxidase 3; GPX3; Ovarian cancer; Papillary serous carcinoma

Indexed keywords

GLUTATHIONE PEROXIDASE 3;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PAPILLARY CARCINOMA; PAPILLARY SEROUS OVARIAN CANCER; PRIORITY JOURNAL; RECURRENT CANCER;

EID: 80054721603     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-4-18     Document Type: Article

References (38)

1. Global Cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Ovarian Cancer Home Page-National Cancer Institute. http://www.cancer. gov/cancertopics/types/ovarian
3. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, Ha M, Choi KH, Clin Chem Lab Med 2011 49 527 534 10.1515/CCLM.2011.085 21320028
4. A Framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD, PLCO Project Team, Cancer Prev Res (Phila) 2011 4 375 383 10.1158/1940-6207.CAPR-10-0193
5. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N, Cancer Prev Res (Phila) 2011 4 365 374 10.1158/1940-6207.CAPR-10-0195
6. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Mai PL, Wentzensen N, Greene MH, Cancer Prev Res (Phila) 2011 4 303 306 10.1158/1940-6207.CAPR-11-0053
7. Use of proteomic patterns in serum to identify ovarian cancer. Petricoin EF, Ardekani AM, Hitt BA, et al. Lancet 2002 359 572 577 10.1016/S0140-6736(02) 07746-2 11867112 (Pubitemid 34178440)
8. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW, Cancer Res 2004 64 5882 5890 10.1158/0008-5472.CAN-04-0746 15313933 (Pubitemid 39095590)
9. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE, Cancer Epidemiol Biomarkers Prev 2005 14 981 987 10.1158/1055-9965.EPI-04-0404 15824174 (Pubitemid 40478567)
10. Diagnostic markers for early detection of ovarian cancer. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G, Clin Cancer Res 2008 14 1065 1072 10.1158/1078-0432.CCR-07-1569 18258665 (Pubitemid 351302552)
11. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Zhang Z, Chan DW, Cancer Epidemiol Biomarkers Prev 2010 19 2995 2999 10.1158/1055-9965.EPI-10-0580 20962299
12. Regulation of autophagy by reactive oxygen species (ROS): Implications for cancer progression and treatment. Azad MB, Chen Y, Gibson SB, Antioxid Redox Signal 2009 11 777 790 10.1089/ars.2008.2270 18828708
13. ROS stress in cancer cells and therapeutic implications. Pelicano H, Carney D, Huang P, Drug Resist Updat 2004 7 97 110 10.1016/j.drup.2004.01.004 15158766 (Pubitemid 38736063)
14. Hypoxia-A key regulatory factor in tumor growth. Harris AL, Nat Rev Cancer 2002 2 38 47 10.1038/nrc704 11902584 (Pubitemid 37328806)
15. Oxidative stress in tumor angiogenesis-therapeutic targets. Tertil M, Jozkowicz A, Dulak J, Curr Pharm Des 2010 16 3877 3894 10.2174/ 138161210794454969 21158725
16. Hypoxic stress and cancer: imaging the axis of evil in tumor metastasis. Avni R, Cohen B, Neeman M, NMR Biomed 2011
17. Glutathione peroxidases in different stages of carcinogenesis. Brigelius-Flohé R, Kipp A, Biochim Biophys Acta 2009 1790 1555 1568 19289149
18. Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer. Pawowicz Z, Zachara BA, Trafikowska U, Maciag A, Marchaluk E, Nowicki A, J Trace Elem Electrolytes Health Dis 1991 5 275 277 1822338
19. Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma. Falck E, Karlsson S, Carlsson J, Helenius G, Karlsson M, Klinga-Levan K, Cancer Cell Int 2010 10 46 54 10.1186/1475-2867-10-46 21106063
20. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M, Arivazhagan A, Balasubramaniam A, Hegde AS, Chandramouli BA, Santosh V, Rao MR, Kondaiah P, Somasundaram K, Cancer Epidemiol Biomarkers Prev 2010 19 1409 1422 10.1158/1055-9965.EPI-09-1077 20530493
21. Identification of GPX3 epigenetically silenced by CpG methylation in human esophageal squamous cell carcinoma. He Y, Wang Y, Li P, Zhu S, Wang J, Zhang S, Dig Dis Sci 2011 56 681 688 10.1007/s10620-010-1369-0 20725785
22. Functional epigenomics identifies genes frequently silenced in prostate cancer. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H, Cancer Res 2005 15 4218 4227 (Pubitemid 40775660)
23. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Yu YP, Yu G, Tseng G, Cieply K, Nelson J, Defrances M, Zarnegar R, Michalopoulos G, Luo JH, Cancer Res 2007 67 8043 8050 10.1158/0008-5472.CAN-07-0648 17804715 (Pubitemid 47395138)
24. Immunohistochemical evidence for the over-expression of glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma. Lee HJ, Do JH, Bae S, Yang S, Zhang X, Lee A, Choi YJ, Park DC, Ahn WS, Med Oncol 2010
25. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Saga Y, Ohwada M, Suzuki M, Konno R, Kigawa J, Ueno S, Mano H, Oncol Rep 2008 20 1299 1303 19020706
26. Coordinately up-regulated genes in ovarian cancer. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ, Cancer Res 2001 61 3869 3876 11358798 (Pubitemid 32720943)
27. Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP, Mol Cell Proteomics 2009 8 661 9 10.1074/mcp.M800313-MCP200 19047685
28. Modified expression of plasma glutathione peroxidase and manganese superoxide dismutase in human renal cell carcinoma. Sarto C, Frutiger S, Cappellano F, Sanchez JC, Doro G, Catanzaro F, Hughes GJ, Hochstrasser DF, Mocarelli P, Electrophoresis 1999 20 3458 3466 10.1002/(SICI)1522-2683(19991101) 20:17<3458::AID-ELPS3458>3.0.CO;2-5 10608715
29. Thyroidal extracellular glutathione peroxidase: a potential regulator of thyroid-hormone synthesis. Howie AF, Walker SW, Akesson B, Arthur JR, Beckett GJ, Biochem J 1995 308 713 717 8948423
30. Serum selenium and glutathione peroxidase-3 activity: biomarkers of systemic inflammation in the critically ill? Manzanares W, Biestro A, Galusso F, Torre MH, Mãay N, Pittini G, Facchin G, Hardy G, Intensive Care Med 2009 35 882 889 10.1007/s00134-008-1356-5 19034425
31. Identification of GPX3 epigenetically silenced by CpG methylation in human esophageal squamous cell carcinoma. Ye He Y, Wang Y, Li P, Zhu S, Wang J, Zhang S, Dig Dis Sci 2011 56 681 8 10.1007/s10620-010-1369-0 20725785
32. An 8-gene signature, including methylated and down-regulated glutathione peroxidase 3, of gastric cancer. Zhang X, Yang JJ, Kim YS, Kim KY, Ahn WS, Yang S, Int J Oncol 2010 36 405 14 20043075
33. Selenoproteins of the thyroid gland: expression, localization and possible function of glutathione peroxidase 3. Schmutzler C, Mentrup B, Schomburg L, Hoang-Vu C, Herzog V, Köhrle J, Biol Chem 2007 388 1053 1059 10.1515/BC.2007.122 17937619 (Pubitemid 47584302)
34. Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. Fevre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, Jouvet A, Int J Oncol 2009 35 1395 4077 19885562
35. Decreased selenium concentration and glutathione peroxidase activity in blood and increase of these parameters in malignant tissue of lung cancer patients. Zachara BA, Marchaluk-Wisniewska E, Maciaq A, Peplinski J, Skokowski J, et al. Lung 1997 175 321 332 10.1007/PL00007578 9270989 (Pubitemid 27349548)
36. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Lee OJ, Schneider-Stock R, McChesney PA, Kuester D, Roessner A, Vieth M, Moskaluk CA, El-Rifai W, Neoplasia 2005 7 854 61 10.1593/neo.05328 16229808
37. A 2-DE MALDI-TOF study to identify disease regulated serum proteins in lung cancer of c-myc transgenic mice. Chatterji B, Borlak J, Proteomics 2009 9 1044 1056 10.1002/pmic.200701135 19180532
38. Applying Random Forests To Identify Biomarker Panels in Serum 2D-DIGE Data for the Detection and Staging of Prostate Cancer. Fan Y, Murphy TB, Byrne JC, Brennan L, Fitzpatrick JM, Watson RWG, J Proteome Res 2011 10 1361 1373 10.1021/pr1011069 21166384